Navigation Links
SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available

ProStrakan's First U.S. Product Will Be Sold by A Uniquely-Trained Sales


BEDMINSTER, N.J., Nov. 4 /PRNewswire-FirstCall/ -- ProStrakan Group plc (LSE: PSK) today announced that SANCUSO(R) (Granisetron Transdermal System) is now available by prescription for patients with chemotherapy-induced nausea and vomiting (CINV) in the United States. Sancuso was approved by the U.S. Food and Drug Administration (F.D.A.) in September 2008 as the first and only patch to provide up to five consecutive days of control of nausea and vomiting for patients receiving a moderately and/or highly nausea-inducing chemotherapy regimen.

"Chemotherapy-induced nausea and vomiting is one of the most feared side effects of chemotherapy, often times forcing patients to stop important cancer treatments," said company CEO Wilson Totten, MD. "Now, with the availability of Sancuso, healthcare practitioners, patients and caregivers have a new tool in their toolbox to prevent the debilitating side effects of CINV."

Sancuso is a transdermal system, or skin patch, that delivers granisetron, its active component and an established preventor of nausea and vomiting, through a thin layer of adhesive that attaches the patch to the skin on the upper outer arm. The medicine is then released slowly and continuously into the bloodstream for up to five consecutive days.

"As a company dedicated to the needs of the patients, we are thrilled to be launching our first product in the U.S.," added Totten. "The ability to successfully bring Sancuso to the oncology community opens doors for us to introduce other supportive oncology care products, particularly those designed for easier patient use."

A Distinctive Sales Force

In order to better meet the needs of patients and oncology health-care professionals, the Sancuso sales force has been trained by oncology nurses through a partnership with ONSEdge(R), a subsidiary of the Oncology Nursing Society. Each member of the sales force participated in a detailed training program administered by oncology nurses, which focused on both general oncology and CINV.

"We believe that the best way to understand and appreciate the needs of health-care providers is to be trained by them. As a result of our collaboration with ONSEdge, our sales force is well-prepared to discuss SANCUSO in a responsible way and in a manner that will better serve the community at large," said Totten.

ProStrakan's robust 67-person sales force in the U.S. was hired in partnership with NovaQuest, the managed partnership group of Quintiles Transnational.

Additionally, as part of the company's ongoing commitment, ProStrakan has developed a patient assistance program to ensure that Sancuso is available to any qualified patients who would benefit from it. Please visit for additional information. The company is also working with regulatory authorities to bring Sancuso to market in Europe.

About CINV

Chemotherapy-induced nausea and vomiting (CINV) are commonly cited by patients undergoing chemotherapy as highly feared side effects. In addition to its social and emotional effects, if left untreated, CINV can lead to dehydration, malnutrition, treatment delay, or even discontinuation of treatment. Despite advances in treatment, CINV remains a significant problem. Some patients expect to endure unpleasant symptoms in order to continue chemotherapy and may suffer at home while not under the supervision of a health-care professional. With one application of Sancuso, patients receive up to five consecutive days of CINV treatment.

Important Safety Information About SANCUSO(R)

Sancuso is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the patch.

Granisetron may mask a progressive ileus and/or gastric distention caused by the underlying condition. Mild application site reactions have occurred; remove patch if severe reactions or a generalized skin reaction occur. Patients should avoid direct exposure of application site to natural or artificial sunlight by covering with clothing while wearing the patch and for 10 days after removing it.

The most common adverse reaction is constipation. No clinically relevant drug interactions have been reported in clinical studies with Sancuso.

About ProStrakan

ProStrakan is one of Europe's fastest growing pharmaceutical companies, with new U.S. headquarters in Bedminster, New Jersey. ProStrakan is committed to developing innovative therapies to improve the lives of patients. Our current products range from cancer, women's health, men's health, anesthesiology, and cardiovascular disease. For more information on ProStrakan, please visit

SOURCE ProStrakan Group plc
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. First biomarker discovered that predicts prostate cancer outcome
2. FDA Approves First Anti-Psychotic for Kids
3. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
4. First study examines newly-licensed RN work attitudes and intentions
5. Glades General Hospital First in Palm Beach County to Provide On-Site Electronic Birth Registration
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
8. High and mighty: first common height gene identified by researchers behind obesity gene finding
9. APA Comments on FDAs First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder
10. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
11. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
Post Your Comments:
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Leading pediatric ... peers in Washington, D.C., for the 49th Congress of the International Society of ... Vice President of the Center for Cancer and Blood Disorders at Children’s ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... the nation's first interactive health literacy software tool, and the Cancer Patient Education ... of cancer patient education, today announce a new strategic alliance. , As ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... at the University of California Berkeley, and other leading institutions in announcing the ... power of institutions to change the way animals are raised for food. , ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Oct. 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... facility in Las Piedras, Puerto Rico ... blades. Following ... facility sustained minor structural damage, temporary loss of power ... have been completed, manufacturing operations have resumed, and the ...
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical Services, ... solutions for injectable drug administration, today shared the results ... Adapter for improving the intradermal administration of polio vaccines. ... Vaccination Summit in May 2017 by Dr. Ondrej ... Department, World Health Organization (WHO), and recently published in ...
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
Breaking Medicine Technology: